The Expanding Role of GLP-1 Receptor Agonists: Advancing Clinical Outcomes in Metabolic and Mental Health DOI Creative Commons

Mohamad Al Qassab,

M.A. Mneimneh,

Ahmad Jradi

et al.

Current Issues in Molecular Biology, Journal Year: 2025, Volume and Issue: 47(4), P. 285 - 285

Published: April 17, 2025

Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) have emerged as a promising therapeutic option beyond their established role in managing type 2 diabetes mellitus (T2DM) and obesity. Recent research has highlighted beneficial effects on liver, kidney, cardiovascular health, mediated by both direct indirect mechanisms. In the GLP-1 RAs contribute to improvement of metabolic dysfunction-associated steatotic liver disease (MASLD) reducing hepatic fat accumulation, inflammation, oxidative stress. Additionally, they enhance insulin sensitivity lipid metabolism. Similarly, diabetic kidney (DKD), exhibit renoprotective properties mitigating stress, glomerular hypertension. Furthermore, promote natriuresis stabilize renal function. Moreover, present significant benefits, including improved myocardial function, reduced atherosclerosis progression, enhanced endothelial decreased major adverse events (MACEs). emerging evidence suggests may exert substantial neuropsychiatric reductions depressive symptoms, anxiety, substance use behaviors, lowering risk Alzheimer’s disease, Parkinson’s other dementias likely modulation neurotransmitter systems neuroinflammation. Genetic polymorphisms GLP1R gene also impact response, highlighting importance personalized medicine optimizing RA efficacy. This review synthesizes preclinical clinical supporting multifaceted across multiple organ systems, potential glycemic control. As advances, further exploration mechanisms action long-term outcomes, safety effectiveness diverse patient populations will be essential treating conditions.

Language: Английский

Neuropsychiatric adverse events associated with Glucagon-like peptide-1 receptor agonists: a pharmacovigilance analysis of the FDA Adverse Event Reporting System database DOI Creative Commons
Wenchao Lu, Shihan Wang, Huilin Tang

et al.

European Psychiatry, Journal Year: 2025, Volume and Issue: 68(1)

Published: Jan. 1, 2025

Abstract Background Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely used due to their profound efficacy in glycemic control and weight management. Real-world observations have revealed potential neuropsychiatric adverse events (AEs) associated with GLP-1RAs. This study aimed comprehensively investigate characterize these AEs Methods We analyzed GLP-1RA reaction reports using the FDA Adverse Event Reporting System database. Disproportionality analysis reporting odds ratio (ROR) identified eight categories of conducted descriptive time-to-onset (TTO) analyses explored AE signals among individual GLP-1RAs for loss diabetes mellitus (DM) indications. Results 25,110 cases GLP-1RA-related AEs. showed an association headache (ROR 1.74, 95% confidence interval [CI] 1.65–1.84), migraine 1.28, 95%CI 1.06–1.55), olfactory sensory nerve abnormalities 2.44, 1.83–3.25; ROR 1.69, 1.54–1.85). Semaglutide a moderate suicide-related signal population 2.55, 1.97–3.31). The median TTO was 16 days (interquartile range: 3–66 days). Conclusions In this study, we and, first time, detected positive migraine, abnormalities, abnormalities. also observed semaglutide, population. provides reliable basis further investigation However, as exploratory our findings require confirmation through large-scale prospective studies.

Language: Английский

Citations

1
Multifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbidities DOI Creative Commons
Clifford J. Bailey, Peter R. Flatt, J. Michael Conlon

et al.

Peptides, Journal Year: 2025, Volume and Issue: 187, P. 171380 - 171380

Published: March 11, 2025

Recent studies with peptide-based incretin herapies have focussed mainly on the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide and dual tirzepatide that engages receptors for GLP-1 glucose-dependent insulinotropic polypeptide (GIP). Randomised clinical trials 'real-world' confirmed marked glucose-lowering weight-lowering efficacy of these agents across diverse populations. These include different ethnic groups, young elderly individuals without diabetes and/or overweight or obesity. also protections against development progression cardiovascular renal diseases are additive to benefits conferred by improved control blood glucose body weight. Emerging evidence suggests therapies could additionally ameliorate fatty liver disease, chronic inflammation, sleep apnea possibly degenerative bone disorders cognitive decline. New incretin-based peptide in a long-acting glucagon (LY3324954), GLP-1/glucagon agonists (survodutide, pemvidutide, mazdutide, G49), triple GLP-1/GIP/glucagon (retatrutide, efocipegtrutide), combination amylin analogue cagrilintide (CagriSema), unimolecular GLP-1/amylin (amycretin), GIP antibody agonism (MariTide). The creation multi-targeting synthetic peptides provides opportunities management type 2 obesity as well new therapeutic approaches an expanding list associated co-morbidities. aim review is acquaint reader developments field from 2023 present (February 2025).

Language: Английский

Citations

1
Seltorexant for major depressive disorder DOI

Kyle Valentino,

Kayla M. Teopiz, Sabrina Wong

et al.

Expert Opinion on Emerging Drugs, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 10, 2025

Introduction Preclinical and clinical pharmacologic evidence indicate that orexin systems are relevant to sleep-wake cycle regulation dimensions of reward cognition, providing the basis hypothesizing they may be effective as therapeutics in mental disorders. Due limited efficacy tolerability profiles existing treatments for Major Depressive Disorder (MDD), investigational compounds novel treatment classes needed; seltorexant, an receptor antagonist, is a potential new currently under investigation.

Language: Английский

Citations

0
Curbing the appetites and restoring the capacity for satisfaction: the impact of GLP-1 agonists on the reward circuitry DOI Creative Commons
Anna Julia Krupa

Neuroscience Applied, Journal Year: 2025, Volume and Issue: unknown, P. 105512 - 105512

Published: March 1, 2025

Language: Английский

Citations

0
ChatGPT-4o and 4o1 Preview as Dietary Support Tools in a Real-World Medicated Obesity Program: A Prospective Comparative Analysis DOI Open Access
Louis Talay,

Leif Lagesen,

A. W. C. Yip

et al.

Healthcare, Journal Year: 2025, Volume and Issue: 13(6), P. 647 - 647

Published: March 16, 2025

Background/Objectives: Clinicians are becoming increasingly interested in the use of large language models (LLMs) obesity services. While most experts agree that LLM integration would increase access to care and its efficiency, many remain skeptical their scientific accuracy capacity convey human empathy. Recent studies have shown ChatGPT-3 capable emulating dietitian responses a range basic dietary questions. Methods: This study compared two ChatGPT-4o those from dietitians across 10 complex questions (5 broad; 5 narrow) derived patient–clinician interactions within real-world medicated digital weight loss service. Results: Investigators found neither nor Chat GPT-4o1 preview were statistically outperformed (p < 0.05) by on any study’s The same finding was made when scores aggregated ten following four individual criteria: correctness, comprehensibility, empathy/relatability, actionability. Conclusions: These results provide preliminary evidence advanced LLMs may be able play significant supporting role Research other contexts is needed before stronger conclusions about lifestyle coaching whether such initiatives access.

Language: Английский

Citations

0
The effect of GLP-1RAs on mental health and psychotropics-induced metabolic disorders: A systematic review DOI

Sigrid Breit,

Daniela Hubl

Psychoneuroendocrinology, Journal Year: 2025, Volume and Issue: unknown, P. 107415 - 107415

Published: March 1, 2025

Language: Английский

Citations

0
The Expanding Role of GLP-1 Receptor Agonists: Advancing Clinical Outcomes in Metabolic and Mental Health DOI Creative Commons

Mohamad Al Qassab,

M.A. Mneimneh,

Ahmad Jradi

et al.

Current Issues in Molecular Biology, Journal Year: 2025, Volume and Issue: 47(4), P. 285 - 285

Published: April 17, 2025

Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) have emerged as a promising therapeutic option beyond their established role in managing type 2 diabetes mellitus (T2DM) and obesity. Recent research has highlighted beneficial effects on liver, kidney, cardiovascular health, mediated by both direct indirect mechanisms. In the GLP-1 RAs contribute to improvement of metabolic dysfunction-associated steatotic liver disease (MASLD) reducing hepatic fat accumulation, inflammation, oxidative stress. Additionally, they enhance insulin sensitivity lipid metabolism. Similarly, diabetic kidney (DKD), exhibit renoprotective properties mitigating stress, glomerular hypertension. Furthermore, promote natriuresis stabilize renal function. Moreover, present significant benefits, including improved myocardial function, reduced atherosclerosis progression, enhanced endothelial decreased major adverse events (MACEs). emerging evidence suggests may exert substantial neuropsychiatric reductions depressive symptoms, anxiety, substance use behaviors, lowering risk Alzheimer’s disease, Parkinson’s other dementias likely modulation neurotransmitter systems neuroinflammation. Genetic polymorphisms GLP1R gene also impact response, highlighting importance personalized medicine optimizing RA efficacy. This review synthesizes preclinical clinical supporting multifaceted across multiple organ systems, potential glycemic control. As advances, further exploration mechanisms action long-term outcomes, safety effectiveness diverse patient populations will be essential treating conditions.

Language: Английский

Citations

0